Biocon Biologics is a global biosimilars company with a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, and other non-communicable diseases. The company has commercialized eight biosimilars in key emerging markets and advanced markets like the U.S., EU, Australia, Canada, and Japan. Biocon Biologics is focused on using advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. Biocon Biologics is a subsidiary of Biocon Ltd, a publicly listed global biopharmaceuticals company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune. Biocon Ltd has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the U.S. and Europe.
Legal Address
Biocon House, Ground Floor, Tower-3, Semicon Park Electronic City, Phase - Ii, Hosur Road
Bangalore; Karnataka;
Postal Code: 560100
Contact Details: Purchase the Biocon Biologics Limited report to view the information.
Website: http://www.bioconbiologics.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service